EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)

Effects of combined test dose and therapeutic drug monitoring strategy in exposure-directed busulfan

Tomoki Iemura, Tadakazu Kondo, Atsushi Ueda, Takeshi Maeda, Toshio Kitawaki, Yasuyuki Arai, Junya Kanda, Takashi Ikeda, Kazunori Imada, Takayuki Ishikawa, Naoyuki Anzai, Mitsuru Itoh und 13 weitere

Annals of Hematology · 2023

DOI: 10.1007/s00277-023-05209-2 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Annals of Hematology, 2023. Verfasst von Tomoki Iemura und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Oncology, Kyoto University, 54, Shogoin Kawahara-Cho, Sakyo-Ku, Kyoto, 606-8507, Japan. Hauptthemen laut MEDLINE: Hematologic Neoplasms, Hematopoietic Stem Cell Transplantation. Die Arbeit nennt 31 Literaturangaben. Gefördert von: Ministry of Education, Culture, Sports, Science and Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Although exposure-directed busulfan (BU) dosing can improve allogeneic hematopoietic stem cell transplantation outcomes, there is still large variability in BU exposure with test dose alone due to changes in BU clearance caused by drug interactions. We conducted a single-arm phase II trial using the combined test dose and therapeutic drug monitoring strategy (PK-guided group) and compared the outcomes with an external historical cohort receiving a fixed-dose (fixed-dose group). The first eight and second eight doses were adjusted based on the area under the blood concentration-time curve (AUC) of the test and first doses, respectively, targeting a total AUC of 82.1 mg·h/L. All patients received either BU and cyclophosphamide conditioning (BU/CY) or fludarabine (FLU)-containing conditioning. The BU clearance at the first dose decreased more in patients receiving FLU than in those receiving BU/CY; however, BU clearance also declined over time in patients who received BU/CY. The simulated total AUC (sAUC) with test dose only was significantly higher in patients who received FLU than in those who received BU/CY, but sAUC with the combined strategy was comparable. The 100-day progression-free survival was 85.5% (95% confidence interval [CI]: 71.9-92.8%), and was not inferior to that in the fixed-dose group. For the FLU-containing regimens, the PK-guided group showed decreased relapse (0.0% vs. 26.9%, p = 0.03), and favorable overall survival (75.1% vs. 57.0%, p = 0.07) at 1 year. The combined strategy effectively controlled the BU exposure close to the target levels, potentially improving efficacy, especially in patients receiving the FLU-containing regimen. Clinical evaluation of efficacy of dose-modified intravenous busulfan in allogeneic hematopoietic stem cell transplantation for hematological malignancy (#UMIN000014077, June 15th, 2014).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematologic NeoplasmsHematopoietic Stem Cell TransplantationHumansBusulfanCyclophosphamideDrug MonitoringNeoplasm Recurrence, LocalTransplantation ConditioningVidarabine

Stichwörter der Autor:innen

Allogeneic hematopoietic stem cell transplantationBusulfanPretransplant conditioningTherapeutic drug monitoring

Substanzen

BusulfanCyclophosphamideVidarabine

Autor:innen und Institutionen

  • Department of Hematology and Oncology, Kyoto University, 54, Shogoin Kawahara-Cho, Sakyo-Ku, Kyoto, 606-8507, Japan.
  • Department of Hematology and Oncology, Kyoto University, 54, Shogoin Kawahara-Cho, Sakyo-Ku, Kyoto, 606-8507, Japan. tadakazu@kuhp.kyoto-u.ac.jp.
  • Department of Hematology, Kurashiki Central Hospital, Okayama, Japan.
  • Department of Clinical Laboratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Division of Hematology and Stem Cell Transplantation, Shizuoka Cancer Center, Shizuoka, Japan.
  • Department of Hematology, Japanese Red Cross Osaka Hospital, Osaka, Japan.

Förderung

  • Ministry of Education, Culture, Sports, Science and Technology

Zitieren

APA

Iemura, T., Kondo, T., Ueda, A., Maeda, T., Kitawaki, T., Arai, Y., Kanda, J., Ikeda, T., Imada, K., Ishikawa, T., Anzai, N., Itoh, M., Takeoka, T., Akasaka, T., Yago, K., Yonezawa, A., Arima, N., Kitano, T., Nohgawa, M., …, & Takaori-Kondo, A. (2023). Effects of combined test dose and therapeutic drug monitoring strategy in exposure-directed busulfan. Annals of Hematology. https://doi.org/10.1007/s00277-023-05209-2

Vancouver

Iemura T, Kondo T, Ueda A, Maeda T, Kitawaki T, Arai Y, et al. Effects of combined test dose and therapeutic drug monitoring strategy in exposure-directed busulfan. Annals of Hematology. 2023. doi:10.1007/s00277-023-05209-2

BibTeX
@article{Iemura2023,
  author = {Iemura, Tomoki and Kondo, Tadakazu and Ueda, Atsushi and Maeda, Takeshi and Kitawaki, Toshio and Arai, Yasuyuki and Kanda, Junya and Ikeda, Takashi and Imada, Kazunori and Ishikawa, Takayuki and Anzai, Naoyuki and Itoh, Mitsuru and Takeoka, Tomoharu and Akasaka, Takashi and Yago, Kazuhiro and Yonezawa, Akihito and Arima, Nobuyoshi and Kitano, Toshiyuki and Nohgawa, Masaharu and Watanabe, Mitsumasa and Moriguchi, Toshinori and Yamashita, Kouhei and Ueda, Yasunori and Matsumoto, Kana and Takaori-Kondo, Akifumi},
  title = {Effects of combined test dose and therapeutic drug monitoring strategy in exposure-directed busulfan},
  journal = {Annals of Hematology},
  year = {2023},
  doi = {10.1007/s00277-023-05209-2}
}
Kostenlos starten →